Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTQ1062 in HR+/HER2- Advanced Breast Cancer
NCT07393321Phase 3Not yet recruiting
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- Feb 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Hormone receptor-positive breast cancer comparing NTQ1062 + Fulvestrant with Placebo + Fulvestrant (2 arms). Primary endpoint: Progression-Free Survival at 60 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
NTQ1062
03
Conditions
Hormone receptor-positive breast cancer
Beyond the preview
Go deeper on NCT07393321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07393321.